2-Chloro-5-isopropylbenzoic acid | 1160575-02-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-Chloro-5-isopropylbenzoic acid
• 英文别名: 2-chloro-5-propan-2-ylbenzoic acid
• CAS: 1160575-02-9
• 化学式: C₁₀H₁₁ClO₂
• 分子量: 198.64
• InChiKey: MXEPLXPXXYZIPE-UHFFFAOYSA-N

物化性质

• 沸点：
  302.4±30.0 °C(Predicted)
• 密度：
  1.211±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• [EN] 4-OXO-3,4-DIHYDROQUINAZOLINE COMPOUNDS AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION<br/>[FR] COMPOSÉS DE 4-OXO-3,4-DIHYDROQUINAZOLINE UTILISÉS EN TANT QU'INHIBITEURS DE LA RÉPLICATION DU VIRUS DE L'IMMUNODÉFICIENCE HUMAINE
  申请人：VIIV HEALTHCARE UK NO 5 LTD

  公开号：WO2019198024A1

  公开（公告）日：2019-10-17

  Compounds of Formula (I), including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth: Formula (I):

  化合物的公式（I），包括其药用盐，以及用于治疗人类免疫缺陷病毒（HIV）感染的组合物和方法如下：公式（I）：
• MODULATORS OF ATP-BINDING CASSETTE-TRANSPORTERS
  申请人：Hadida Ruah Sara S.

  公开号：US20130296364A1

  公开（公告）日：2013-11-07

  Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.

  本发明的化合物及其药学上可接受的组合物可用作ATP结合盒（“ABC”）转运蛋白或其片段的调节剂，包括囊性纤维化跨膜传导调节因子（“CFTR”）。本发明还涉及使用本发明的化合物治疗ABC转运蛋白介导的疾病的方法。
• SUBSTITUTED PHENYL-SPLEEN TYROSINE KINASE (SYK) INHIBITORS
  申请人：Merck Sharp & Dohme Corp.

  公开号：US20150232428A1

  公开（公告）日：2015-08-20

  The invention provides certain substituted phenyl compounds of the Formula (I) or pharmaceutically acceptable salts thereof, wherein R 1 , R 2 , R 3 , R 4 , R cy , and t are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions mediated by Spleen Tyrosine Kinase (Syk).

  本发明提供了公式(I)或其药学上可接受的盐的某些取代苯基化合物，其中R1、R2、R3、R4、Rcy和t如本文中所定义。本发明还提供了包括这些化合物的制药组合物以及使用这些化合物治疗Spleen Tyrosine Kinase（Syk）介导的疾病或病症的方法。
• Substituted tetrahydropyrans as CCR2 modulators
  申请人：CHEMOCENTRYX, INC.

  公开号：US10464934B2

  公开（公告）日：2019-11-05

  Compounds are provided that are modulators of the CCR2 receptor. The compounds have the general formula (I): and are useful in pharmaceutical compositions, methods for the treatment of diseases and disorders involving the pathologic activation of CCR2 receptors.

  所提供的化合物是 CCR2 受体的调节剂。这些化合物具有通式 (I)： 并可用于药物组合物、治疗涉及 CCR2 受体病理性激活的疾病和失调的方法。
• Methods of treating solid tumors with CCR2 antagonists
  申请人：CHEMOCENTRYX, INC.

  公开号：US11154556B2

  公开（公告）日：2021-10-26

  The present disclosure provides, inter alia, methods of treating a solid-tumor by administering an effective amount of a Chemokine Receptor 2 (CCR2) antagonist. Also provided herein are methods of reducing the number of macrophages in a solid tumor microenvironment, said method comprising administering effective amount of a Chemokine Receptor 2 (CCR2) antagonist. In an additional aspect, the current disclosure further provides methods of increasing the number CD8+ T cells in a solid tumor microenvironment, said method comprising administering effective amount of a Chemokine Receptor 2 (CCR2) antagonist. In some embodiments, the CCR2 antagonist has the formula I:

  本公开特别提供了通过施用有效量的趋化因子受体2（CCR2）拮抗剂来治疗实体瘤的方法。本文还提供了减少实体瘤微环境中巨噬细胞数量的方法，所述方法包括施用有效量的趋化因子受体2（CCR2）拮抗剂。在另一个方面，本公开进一步提供了增加实体瘤微环境中 CD8+ T 细胞数量的方法，所述方法包括施用有效量的趋化因子受体 2 (CCR2)拮抗剂。在某些实施方案中，CCR2拮抗剂具有式I：